Key clinical point: Switching calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb) may benefit patients with episodic migraine (EM) or chronic migraine (CM) who had failed to respond to the first CGRP-mAb or experienced a loss of efficacy over time.
Major finding : Overall, 71.9% of patients responded to the first CGRP-mAb, 42.3% of those who did not respond or experienced a loss of efficacy over time to the first CGRP-mAb responded to the second CGRP-mAb, and 28.6% of patients who received the third CGRP-mAb showed a response.
Study details: Findings are from a retrospective, real-world case series including 171 patients with EM or CM who received one (n = 137), two (n = 27), or all three(n = 7) CGRP-mAb as migraine preventive therapy.
Disclosures: This study received no specific funding from any source. Some authors declared receiving personal fees, unrestricted grants, honoraria, or travel grants from various sources.
Source: Kaltseis K et al. Monoclonal antibodies against CGRP (R): Non-responders and switchers: Real world data from an Austrian case series. BMC Neurol. 2023;23(1):174 (Apr 28). doi: 10.1186/s12883-023-03203-9